Clinical impact of circulating tumor DNA to track minimal residual disease in colorectal cancer patients. Hopes and limitations

C. Soueidy; A. Zaanan; M. Gelli; E. Moati; C. Gallois; V. Taly; P. Laurent-Puig; L. Benhaim; J. Taieb

ESMO Gastrointestinal Oncology (Jun 2024)

Clinical impact of circulating tumor DNA to track minimal residual disease in colorectal cancer patients. Hopes and limitations

C. Soueidy,
A. Zaanan,
M. Gelli,
E. Moati,
C. Gallois,
V. Taly,
P. Laurent-Puig,
L. Benhaim,
J. Taieb

Affiliations

C. Soueidy: Department of Gastroenterology and Digestive Oncology, Georges-Pompidou European Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP-Paris Centre), Université de Paris, Paris, France; Hematology and Oncology Department, Hotel Dieu de France Hospital, Université Saint Joseph de Beyrouth, Beirut, Lebanon
A. Zaanan: Department of Gastroenterology and Digestive Oncology, Georges-Pompidou European Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP-Paris Centre), Université de Paris, Paris, France; Centre de Recherche des Cordeliers, INSERM, Sorbonne Université, Université de Paris Cité, CNRS SNC 5096, Paris
M. Gelli: Department of Surgery and Visceral Oncology, Gustave Roussy, Cancer Campus, Villejuif, France
E. Moati: Department of Gastroenterology and Digestive Oncology, Georges-Pompidou European Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP-Paris Centre), Université de Paris, Paris, France
C. Gallois: Department of Gastroenterology and Digestive Oncology, Georges-Pompidou European Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP-Paris Centre), Université de Paris, Paris, France; Centre de Recherche des Cordeliers, INSERM, Sorbonne Université, Université de Paris Cité, CNRS SNC 5096, Paris
V. Taly: Centre de Recherche des Cordeliers, INSERM, Sorbonne Université, Université de Paris Cité, CNRS SNC 5096, Paris
P. Laurent-Puig: Centre de Recherche des Cordeliers, INSERM, Sorbonne Université, Université de Paris Cité, CNRS SNC 5096, Paris
L. Benhaim: Centre de Recherche des Cordeliers, INSERM, Sorbonne Université, Université de Paris Cité, CNRS SNC 5096, Paris; Department of Surgery and Visceral Oncology, Gustave Roussy, Cancer Campus, Villejuif, France
J. Taieb: Department of Gastroenterology and Digestive Oncology, Georges-Pompidou European Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP-Paris Centre), Université de Paris, Paris, France; Centre de Recherche des Cordeliers, INSERM, Sorbonne Université, Université de Paris Cité, CNRS SNC 5096, Paris; Correspondence to: Prof. Julien Taieb, HEGP 20 rue leblanc, 75015 Paris.

Journal volume & issue: Vol. 4
p. 100068

Abstract

Read online

Circulating tumor DNA (ctDNA) has been studied as a non-invasive tool for disease monitoring in different cancer types. Despite advances in colorectal cancer (CRC) management, it remains a leading cause of mortality and there is an unmet need for new biomarkers to guide therapeutic approaches and improve patient’s outcome after surgical resection of the primary tumor or its metastatic sites. This review summarizes the different clinical results and ongoing studies on the performances of ctDNA as a prognostic marker for disease recurrence, both in non-metastatic patients with resection of the primary tumor and in those with full resection of metastatic disease.

Published in ESMO Gastrointestinal Oncology

ISSN: 2949-8198 (Online)
Publisher: Elsevier
Country of publisher: United Kingdom
LCC subjects: Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Website: https://www.sciencedirect.com/journal/esmo-gastrointestinal-oncology

About the journal

Abstract

Keywords